China SXT Pharmaceuticals (SXTC) Liabilities and Shareholders Equity (2018 - 2026)

China SXT Pharmaceuticals (SXTC) has reported Liabilities and Shareholders Equity for 9 consecutive years, with $34.8 million the latest figure, recorded in Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 60.43% year-over-year to $34.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $113.8 million (up 25.88% YoY) and the FY2026 annual result came in at $34.8 million, up 60.43% from the prior year.
• Liabilities and Shareholders Equity climbed to $34.8 million in Q1 2026 per SXTC's latest filing, from $26.4 million in the prior quarter.
• Over the last five years, Liabilities and Shareholders Equity for SXTC reached as high as $34.8 million in Q1 2026 and fell as low as $14.6 million in Q3 2023.
• A 5-year average of $26.3 million and a median of $26.4 million in 2025 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2023 — Liabilities and Shareholders Equity tumbled 34.23% — and 2024, when it soared 112.49%.
• Year by year, Liabilities and Shareholders Equity stood at $22.2 million in 2022, then slumped by 34.23% to $14.6 million in 2023, then surged by 112.49% to $31.0 million in 2024, then fell by 14.98% to $26.4 million in 2025, then jumped by 31.88% to $34.8 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $34.8 million, $26.4 million, and $21.7 million for Q1 2026, Q3 2025, and Q1 2025 respectively.